Investigational drug · Phase 3
Neladalkib
Also called: NVL-655
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive, Locally Advanced Solid Tumor.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Neladalkib"
First trial start
2022
Jun 9, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Neladalkib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Anaplastic Lymphoma Kinase-positive
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Neladalkib" as an intervention, largest first.
Nuvalent Inc.Industry
NCT05384626 · 840 participants (planned) · Start Jun 9, 2022 · Primary completion Dec 2027
Drug: Neladalkib (NVL-655); Midazolam and 2 more · For: Locally Advanced Solid Tumor; Metastatic Solid Tumor
Sites: Orange, California; Sacramento, California; Stanford, California · 74 sites in all
- Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCPivotal-lookingRecruiting
Nuvalent Inc.Industry
NCT06765109 · 450 participants (planned) · Start Jul 17, 2025 · Primary completion Dec 2029
Drug: Neladalkib (NVL-655); Alectinib · For: Non-small Cell Lung Cancer; Anaplastic Lymphoma Kinase-positive
Sites: Glendale, Arizona; Newport Beach, California; Orange, California · 159 sites in all
TRIANA Biomedicines, Inc.Industry
NCT07491497 · 160 participants (planned) · Start Mar 11, 2026 · Primary completion May 31, 2029
Drug: TRI-611 · For: ALK-positive NSCLC; ALK-Positive Lung Cancer; ALK-positive Non-small Cell Lung Cancer
Sites: San Francisco, California; Aurora, Colorado; Boston, Massachusetts · 20 sites in all
Nuvalent Inc.Industry
NCT06834074
Drug: NVL-655 · For: Non Small Cell Lung Cancer; ALK-positive Non-small Cell Lung Cancer (NSCLC)
Sites: Orange, California; Aurora, Colorado; Chicago, Illinois · 50 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.
Nagasaka M, Facchinetti F, Bigot L, et al. · NPJ Precis Oncol 2026
- Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib.
Ou SI, Park CJ, Arter ZL, et al. · Lung Cancer (Auckl) 2025
- Preclinical Prediction of Resistance Mutations and Proposal of Sequential Treatment Strategies for ALK-positive Lung Cancer Using Next-generation ALK Inhibitors.
Takei Y, Kuroiwa H, Arai C, et al. · Pharm Res 2025
- Prediction of potential drug-resistant ALK mutations against fourth-generation inhibitors NVL-655 and TPX-0131.
Zhao F, Xia W, Wang Y, et al. · Int J Biol Macromol 2025
- Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting.
van der Wel JWT, de Langen AJ · Lung Cancer 2025
- NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Lin JJ, Horan JC, Tangpeerachaikul A, et al. · Cancer Discov 2024
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.